What Happened To Puma Biotechnology?

Puma Biotechnology ’s shares are getting pounded today after its breast cancer drug neratinib suffered a regulatory setback that makes a 2018 European launch unlikely. One analyst says the news “makes the M&A narrative more challenging. ”

Source: Forbes.com Healthcare News - January 24, 2018 Category: Pharmaceuticals Authors: Johanna Bennett, Contributor Tags: NASDAQ:PBYI Source Type: news